retatrutide clinical trial results ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with obesity or “overweight” Best Retatrutide Peptide (Triple Agonist)

A master protocol for orforglipron (LY3502970) in participants with hypertension and obesity or overweight: (ATTAIN-Hypertension screening)

Novo Nordisk, a competitor to Eli Lilly, has already sought FDA approval for an oral semaglutide pill, its oral GLP-1 pill, and is expected to receive a decision by the end of this year

Lost your medication

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial

None of these are approved for human use in France research use only.

Because these drugs reduce appetite, many people eat less overall and accidentally fall short on protein